Annual SG&A
$28.88 M
-$1.77 M-5.76%
31 December 2023
Summary:
Prelude Therapeutics Incorporated annual selling, general & administrative expenses is currently $28.88 million, with the most recent change of -$1.77 million (-5.76%) on 31 December 2023. During the last 3 years, it has risen by +$18.30 million (+172.85%). PRLD annual SG&A is now -5.76% below its all-time high of $30.65 million, reached on 31 December 2022.PRLD Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$7.92 M
+$264.00 K+3.45%
30 September 2024
Summary:
Prelude Therapeutics Incorporated quarterly selling, general & administrative expenses is currently $7.92 million, with the most recent change of +$264.00 thousand (+3.45%) on 30 September 2024. Over the past year, it has increased by +$795.00 thousand (+11.16%). PRLD quarterly SG&A is now -2.85% below its all-time high of $8.15 million, reached on 30 June 2022.PRLD Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$2.02 B
-$131.52 M-6.96%
30 September 2024
Summary:
Prelude Therapeutics Incorporated TTM selling, general & administrative expenses is currently -$2.02 billion, with the most recent change of -$131.52 million (-6.96%) on 30 September 2024. Over the past year, it has dropped by -$2.05 billion (-6987.21%). PRLD TTM SG&A is now -3903.41% below its all-time high of $31.57 million, reached on 30 June 2022.PRLD TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PRLD Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -5.8% | +11.2% | -6987.2% |
| 3 y3 years | +172.8% | -2.4% | -8523.7% |
| 5 y5 years | +1127.0% | +468.1% | -10000.0% |
PRLD Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -5.8% | +172.8% | -2.9% | +14.2% | -249.8% | at low |
| 5 y | 5 years | -5.8% | +1127.0% | -2.9% | +559.4% | -3903.4% | at low |
| alltime | all time | -5.8% | +1127.0% | -2.9% | +559.4% | -3903.4% | at low |
Prelude Therapeutics Incorporated Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $7.92 M(+3.4%) | $29.55 M(+2.8%) |
| June 2024 | - | $7.66 M(+10.4%) | $28.76 M(+0.8%) |
| Mar 2024 | - | $6.93 M(-1.6%) | $28.54 M(-1.2%) |
| Dec 2023 | $28.88 M(-5.8%) | $7.05 M(-1.1%) | $28.88 M(-1.6%) |
| Sept 2023 | - | $7.12 M(-4.1%) | $29.35 M(-1.3%) |
| June 2023 | - | $7.43 M(+2.1%) | $29.75 M(-2.4%) |
| Mar 2023 | - | $7.28 M(-3.1%) | $30.46 M(-0.6%) |
| Dec 2022 | $30.65 M(+13.7%) | $7.52 M(-0.0%) | $30.65 M(-1.0%) |
| Sept 2022 | - | $7.52 M(-7.8%) | $30.97 M(-1.9%) |
| June 2022 | - | $8.15 M(+9.2%) | $31.57 M(+9.1%) |
| Mar 2022 | - | $7.47 M(-4.7%) | $28.93 M(+7.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | $26.96 M(+154.6%) | $7.83 M(-3.5%) | $26.96 M(+12.3%) |
| Sept 2021 | - | $8.12 M(+47.2%) | $24.00 M(+28.1%) |
| June 2021 | - | $5.51 M(+0.3%) | $18.73 M(+25.9%) |
| Mar 2021 | - | $5.50 M(+12.8%) | $14.88 M(+40.6%) |
| Dec 2020 | $10.59 M(+176.4%) | $4.87 M(+71.0%) | $10.59 M(+52.1%) |
| Sept 2020 | - | $2.85 M(+71.7%) | $6.96 M(+26.5%) |
| June 2020 | - | $1.66 M(+38.2%) | $5.50 M(+43.2%) |
| Mar 2020 | - | $1.20 M(-3.6%) | $3.84 M(+45.5%) |
| Dec 2019 | $3.83 M(+62.7%) | $1.25 M(-10.6%) | $2.64 M(+89.4%) |
| Sept 2019 | - | $1.39 M | $1.39 M |
| Dec 2018 | $2.35 M | - | - |
FAQ
- What is Prelude Therapeutics Incorporated annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Prelude Therapeutics Incorporated?
- What is Prelude Therapeutics Incorporated annual SG&A year-on-year change?
- What is Prelude Therapeutics Incorporated quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Prelude Therapeutics Incorporated?
- What is Prelude Therapeutics Incorporated quarterly SG&A year-on-year change?
- What is Prelude Therapeutics Incorporated TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Prelude Therapeutics Incorporated?
- What is Prelude Therapeutics Incorporated TTM SG&A year-on-year change?
What is Prelude Therapeutics Incorporated annual selling, general & administrative expenses?
The current annual SG&A of PRLD is $28.88 M
What is the all time high annual SG&A for Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated all-time high annual selling, general & administrative expenses is $30.65 M
What is Prelude Therapeutics Incorporated annual SG&A year-on-year change?
Over the past year, PRLD annual selling, general & administrative expenses has changed by -$1.77 M (-5.76%)
What is Prelude Therapeutics Incorporated quarterly selling, general & administrative expenses?
The current quarterly SG&A of PRLD is $7.92 M
What is the all time high quarterly SG&A for Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated all-time high quarterly selling, general & administrative expenses is $8.15 M
What is Prelude Therapeutics Incorporated quarterly SG&A year-on-year change?
Over the past year, PRLD quarterly selling, general & administrative expenses has changed by +$795.00 K (+11.16%)
What is Prelude Therapeutics Incorporated TTM selling, general & administrative expenses?
The current TTM SG&A of PRLD is -$2.02 B
What is the all time high TTM SG&A for Prelude Therapeutics Incorporated?
Prelude Therapeutics Incorporated all-time high TTM selling, general & administrative expenses is $31.57 M
What is Prelude Therapeutics Incorporated TTM SG&A year-on-year change?
Over the past year, PRLD TTM selling, general & administrative expenses has changed by -$2.05 B (-6987.21%)